Wed, Jul 23, 2014, 9:11 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Regenerx Biopharmaceuticals Inc. Message Board

  • fl_geezer fl_geezer Mar 10, 2014 2:51 PM Flag

    Penny Trading Stock

    Given what we have learned now (that the Korean "partner buy-in" was simply a disguised PIPE deal - - Thanks, Joe and the Essex team???)- - - we can expect RGRX to trade between 10 cents and 20 cents until sometime in 2015.
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I didn't think a VC company could do a pipe deal at the 20 million share level, if they tried the normal tactics (which is to immediately sell all of their shares short before the price collapses), by the time they dumped 3 or 4 million shares, they'd never get their price for the remaining 16 million shares. The VC company has to hold these shares, otherwise, they lose.

    • geez….I disagree…you are forgetting the major item that no one knows about, only if you read this board……RGRX is saying nothing about it….the ENGLAND situation. I'd agree with you otherwise…that RGRX is deadweight until they complete another trial shot…..but if England ever does grant a marketing approval for TB 4 in dry eye.…forget RGRX being 10 to 20 cents locked…..RGRX woudl be over $1.00 immediately..maybe even a lot higher. Just depends on what NICE and NHS say…and if they approve it, what was the price Finkelstein offered of TB 4 dry eye….he'd have to cut them a pretty good deal. But the PR of a TB 4 approval would open a lot of peoples eyes. I think we have some more info from England in next 60-90 days. The NICE has sent their info to the NHS.…if the NHS says 'Okay"…..then NICE goes for their final vote…. but NICE wouldn't apply to the NHS for their approval,… unless NICE was willing to approve it themselves.

      I'm hoping RGRX stays soft or down…because only this board knows about england.

 
RGRX
0.162-0.014(-7.74%)Jul 23 3:14 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Gilead Sciences Inc.
NasdaqGSWed, Jul 23, 2014 3:59 PM EDT